ArticleRheumatology international2026
Anti-Toxocara canis seroreactivity across autoimmune rheumatic diseases with exploratory IgG4 and eosinophil-associated signals in systemic lupus erythematosus: a cross-sectional case-control study.
Article in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helminth-related immune responses may intersect with autoimmune rheumatic diseases, but disease-specific patterns remain incompletely understood. This study aimed to investigate anti-Toxocara canis seroreactivity and its immunological and clinical correlates in rheumatoid arthritis, systemic lupus erythematosus, and spondyloarthritis. In this cross-sectional case-control study, 442 individuals were evaluated across disease-specific comparisons. Serology followed a sequential strategy using native T. canis excretory-secretory antigen for initial IgG screening and a recombinant chimeric antigen for confirmatory IgG, IgG1, and IgG4 assessment. Cytokines, eosinophil counts, socioeconomic variables, disease activity, and functional disability were analyzed using adjusted regression models. Total anti-T. canis IgG seroreactivity was frequent across groups. Higher adjusted point estimates were observed in rheumatoid arthritis, systemic lupus erythematosus, and spondyloarthritis. SLE was the only disease group showing a nominally significant association with IgG seroreactivity compared with its respective control group (OR 2.44, 95% CI 1.16-5.14), although no serological association remained significant after FDR correction. SLE also showed a nominal signal of lower IgG4 seroreactivity than controls in the standard adjusted model (OR 0.20, 95% CI 0.04-0.99), but this finding did not remain significant after FDR correction or in small-cell sensitivity analyses. Higher eosinophil counts were associated with lower SLEDAI scores in negative binomial models (IRR per 100 eosinophils/mm³: 0.56, 95% CI 0.36-0.86), and this association persisted after adjustment for medication use, although it should be interpreted as exploratory given the low SLEDAI distribution and limited number of active disease events. Anti-T. canis seroreactivity was frequent across autoimmune rheumatic diseases and showed disease-specific exploratory patterns. In SLE, higher total IgG seroreactivity coexisted with a cautious, hypothesis-generating IgG4 signal, while eosinophil counts showed an exploratory independent association with lower SLEDAI scores. These findings suggest that helminth-related immune signatures may vary across autoimmune disease contexts and should be interpreted as exploratory associations rather than evidence of active infection or causal immunomodulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.